Details for Australian Trade Mark No. 1075707 (hide)

Owner Bristol-Myers Squibb Company a Delaware corporation

Convention US 12 April 2005 78/606737

Service Spruson & Ferguson

Various Convention priority claimed: 12 April 2005, United States of America, No. 78/606737 in respect of PHARMACEUTICAL PREPARATIONS FOR HUMAN USE FOR THE TREATMENT AND PREVENTION OF OBESITY, DIABETES, INCONTINENCE, CARDIOVASCULAR DISEASES, CENTRAL NERVOUS SYSTE

Filing Date 14 September 2005

Classes

Class 5 Pharmaceutical preparations for human use, including those for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection; antibiotics, anti-fungals, anti-virals and immunosuppressants; diagnostic pharmaceutical preparations used to increase heart rate and contrast imaging agents

Class 16 Printed matter, including brochures, letterhead and business cards on the subject of hepatitis B

Class 41 Educational services, including conducting classes, seminars, conferences or workshops in the field of hepatitis B

Event Publications

6 October 2005 Application filed

6 October 2005 Application Accepted

9 February 2006 Trade Mark Registered/Protected

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the ATMOSS Australian Trade Mark On-line Search System.

Next and Previous Trademarks/Applications

1075708

1075706-ARGIRELINE